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Obesity and the risk of type 2 diabetes  
mellitus and certain types of cancer 
Otyłość a ryzyko rozwoju cukrzycy typu 2 i niektórych nowotworów złośliwych
ABSTRACT
Obesity, type 2 diabetes mellitus and cancers are the 
most common chronic diseases. Data collected by 
world organizations for protection and promotion 
of health show a rapid increase in the prevalence of 
these illnesses over the last few decades. The rapid 
increase in prevalence of excess body weight globally 
is believed to be related to the growing proportion of 
people living in urban areas and the resulting changes 
in dietary and physical activity patterns. 
The epidemic of overweight and obesity and the clear 
connection between raised BMI and many non-com-
municable diseases (such as cardiovascular diseases, 
type 2 diabetes, and cancers) make this issue a public 
health priority all over the world. 
Estimates of future overweight and obesity prevalence 
assume that while keeping the current growth rate of 
prevalence, the numbers of people affected around 
the globe will rise to 2.16 billion for overweight and 
1.12 billion for obesity in 2030. These numbers com-
bined will constitute 58% of the world’s population. 
Considering the above, we should expect a propor-
tional increase in prevalence of the most serious health 
consequences of overweight and obesity — type 2 
diabetes mellitus and some cancers, including breast 
cancer in postmenopausal women, endometrial, co-
lonic and renal cancers.
In this paper we discussed the available data on 
prevalence of overweight and obesity and analysed 
a causal relationship between excess body weight, 
type 2 diabetes mellitus and selected types of malig-
nancies. (Diabet. Klin. 2015; 4, 4: 163–171)
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STRESZCZENIE
Zarówno otyłość, jak i cukrzycę typu 2 oraz nowotwory 
złośliwe należy zaliczyć do najczęściej występujących 
obecnie schorzeń przewlekłych. Dane gromadzone 
przez światowe organizacje zajmujące się ochroną 
i promocją zdrowia wskazują na gwałtowny wzrost 
zapadalności na te choroby w ciągu ostatnich kilku 
dziesięcioleci. 
Przyczyn wzrostu rozpowszechnienia nadmiernej 
masy ciała na świecie upatruje się w zwiększającym 
się odsetku osób zamieszkujących tereny miejskie 
oraz wiążącym się z tym trybem życia. Wzrastający 
odsetek nadwagi oraz otyłości w populacji światowej 
oraz jej związek z występowaniem wielu schorzeń 
czyni je istotnym wyzwaniem dla zdrowia publicznego 
i priorytetem światowej polityki zdrowotnej. Prognozy 
dotyczące występowania nadwagi i otyłości zakładają, 
że przy utrzymaniu aktualnego tempa wzrostu rozpo-
wszechnienia częstość ich występowania na świecie 
wzrośnie do 2,16 mld osób w przypadku nadwagi oraz 
1,12 mld osób w przypadku otyłości w 2030 roku, co 
łącznie będzie stanowić 58% populacji świata. Mając 
na względzie powyższe dane, należy spodziewać się 
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równie nasilonego wzrostu występowania najpoważ-
niejszych konsekwencji zdrowotnych otyłości, jakimi 
są m.in. cukrzyca typu 2 oraz wybrane nowotwory 
złośliwe, w tym nowotwory piersi u kobiet będących 
po menopauzie, nowotwory endometrium, jelita gru-
bego oraz nerki.
W publikacji omówiono dostępne dane dotyczące 
epidemiologii oraz związku przyczynowo-skutkowego 
pomiędzy nadmierną masą ciała a ryzykiem rozwoju 
cukrzycy typu 2 oraz wybranych nowotworów złośli-
wych. (Diabet. Klin. 2015; 4, 4: 163–171)
Słowa kluczowe: otyłość, nowotwory, cukrzyca  
typu 2, BMI
Introduction
Overweight and obesity are the effects of distur-
bances in the body’s energy processes. They occur when 
the amount of energy delivered to the body exceeds the 
expended energy for a long time. The resulting excess 
energy is then accumulated in the form of adipose 
tissue [1]. According to the World Health Organiza-
tion (WHO), obesity is abnormal or excessive fat tissue 
accumulation leading to a significant deterioration of 
health. A measure commonly used to determine the 
degree of overweight and obesity in adults is body 
mass index (BMI), also known as Quetelet index, defined 
as the ratio of body weight in kilograms to height in 
metres squared. According to the WHO definition, 
overweight occurs when in adults this ratio has a value 
in the range of 25 to 29.5 kg/m2. BMI value higher than 
30 kg/m2 indicates obesity [2].
Obesity is an increasingly growing population 
problem in the world [3]. Numerous epidemiological 
studies have shown a constantly increasing share of 
obese and overweight people in the general popula-
tion [4]. The reasons for this significant increase in the 
prevalence of overweight and obesity are seen in the 
development of civilisation entailing lifestyle changes, 
significant from the health point of view, which in-
volve a substantial reduction of physical activity while 
introducing high-energy diet (excessive consumption 
of highly processed and high-calorie foods) [5]. Other 
factors affecting the prevalence of overweight and 
obesity in populations are genetic and environmental 
factors [1].
It is well known that excessive body weight can 
lead to significant health consequences, including 
type 2 diabetes, cardiovascular disease, lipid disor-
ders, gout, respiratory disorders and disorders of the 
musculoskeletal system [6–8]. As shown in numerous 
studies, obesity is also associated with a higher risk of 
developing malignancies, including breast cancer in 
postmenopausal women, endometrial cancer, colorec-
tal carcinoma and kidney cancer [9].
Below we discuss the available data on epidemio-
logy and causal relationship between abnormal body 
weight and the risk of developing type 2 diabetes and 
selected cancers.
Obesity is a growing epidemiological 
problem in the 21st century
Due to the significant prevalence in populations, 
obesity has been classified as a disease of civilisation. 
Prior to 1980, excess body weight was not a significant 
epidemiological problem and its prevalence in the 
world was well below 10%. Since then, the prevalence 
of overweight and obesity doubled or even tripled in 
selected countries [10, 11].
According to World Health Organization data, the 
prevalence of obesity has more than doubled over the 
years 1980–2014. In 2014, more than 1.9 billion of 
the world’s adult population were people with excess 
body weight (BMI > 25 kg/m2), including approximately 
600 million with obesity. This means that in 2014 thir-
teen (13) % of the global population aged 18 years or 
older, including 11% of men and 15% of women, were 
obese, and 39% (38% of men and 40% women) were 
overweight. This problem is increasingly more common 
also among children [2].
An analysis prepared by the Organisation for Eco-
nomic Co-operation and Development (OECD) revealed 
that in 2010 more than half of all adult citizens of the 
European Union (52%) were overweight. The preva-
lence of overweight and obesity exceeded 50% in 18 of 
the 27 member states of the European Union. Data 
collected by the OECD also demonstrate significant 
differences between Member States in the prevalence 
of obesity — from approximately 8% in Romania and 
Switzerland to 25% in Hungary and the UK. The aver-
age incidence of obesity in the 27 EU member states in 
2010 was 17%. The collected data also indicate a more 
than twofold increase in the prevalence of obesity in 
selected countries over the last 20 years [12].
According to the results of National Health and 
Nutrition Examination Survey (NHANES) cross-sectional 
study, conducted in the years 2011–2012, in the USA 
obesity was diagnosed in about 35% adults and 17% 
children between 2 and 19 years of age. In the adult 
population the highest incidence of obesity was found 
in the age group 40–59 years (39.5% vs. 30.3% for 
the age group 20–39 years and 35.4% for the age 
group ≥ 60 years). Analysis of the data from years 
2003–2004 and 2011–2012 demonstrated the greatest 
increase of obesity rate (percentage of obese people 
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in the studied population) for the group of women 
aged > 60 years (31.5% in the years 2003–2004 vs. 38% 
in the years 2011–2012). No significant differences 
were found for obesity rates in children (17.1% in the 
years 2003–2004 vs. 16.9% in the years 2011–2012). 
Analysis performed in age subgroups revealed a sig-
nificant decrease of the percentage of obese children 
in the age group from 2 to 5 years (14% in the years 
200–2004 vs. 8% in the years 2011–2012) [13]. The 
prevalence of obesity in the Polish population was ana-
lysed, among others, in the national population-based 
studies, NATPOL PLUS and WOBASZ. The percentages 
of people with overweight and obesity presented in 
the NATPOL PLUS study for 2002 were 29% and 19% 
for women and 39% and 19% for men, respectively, 
which gives the combined percentage of people with 
a BMI > 25 kg/m2 of 52.7% [14, 15]. In the WOBASZ 
study, presenting data from the years 2003–2005, 
overweight and obesity were present in 27.9% and 
20.2% of women and 40.4% and 20.6% of men, re-
spectively, which gives the percentages of individuals 
with a BMI > 25 kg/m2 equal to 50.3% for women, and 
61.6% for men [14, 15]. The most recent, cross-sec-
tional epidemiological study NATPOL 2011, which was 
an extension of the NATPOL PLUS study, showed that 
in 2011, the problem of obesity affected as many as 
approximately 25% of men in Poland, which means an 
increase by 5% over the last 10 years [16, 17].
Also, epidemiological analyses carried out by the 
Central Statistical Office of Poland (CSO) for the years 
2004 and 2009 demonstrated a continuous increase in 
the average body weight of Poles [18, 19]. According 
to the CSO, in 2009, 15.2% of women and 16.6% of 
men were obese, and 29.4% of women and 44.8% of 
men were overweight, giving a total of approximately 
53% of Poland’s adult population with excessive body 
weight [19]. The results of CSO research have also 
shown an increase in the percentage of obese and 
overweight people relative to figures of 1996 by 19 per 
cent points among women and by 32 per cent points 
in men [20]. In a report published by the CSO, “Health 
and health care in 2011”, it was estimated that ap-
proximately 54% of adult Poles (64% of men and 46% 
of women) had excessive body weight [21].
Data collected by the OECD indicate that the epi-
demic of obesity shows no signs of stopping; however, 
its increase seems to be slower than in the previous 
5 years [22]. Over the period of the last 10 years the 
percentages of people with overweight and obesity in 
the populations have stabilised in Italy, England, the 
United States, and only slightly increased in Canada, 
Korea and Spain. The country with the largest increase 
in severity of obesity is France, where the proportion 
of obese people reached a value higher than predicted 
over 10 years. However, it should be emphasised that, 
despite the almost doubling of obesity rates in France, 
the percentage is still lower than in the United King-
dom, which is among the countries with the highest 
percentage of people with a BMI > 25 kg/m2 [22].
While so far obesity has been considered the 
problem of rich countries with a high degree of ur-
banisation, today we can see that it is also a growing 
problem in countries with medium and low national 
income (according to the World Bank classification) [2]. 
One example here is Mexico, where, according to the 
OECD data, the prevalence of overweight in the general 
population increased from 62.1% to 69.9% and obesity 
from 23.7% to 30.4% in the period 2000–2006 [10].
Correlation analyses between the occurrence rates 
of overweight and obesity and socioeconomic fac-
tors suggest a higher incidence of obesity in groups 
with lower economic status. This trend is particularly 
evident in the case of women [23, 24]. There was also 
a correlation between the level of education and obe-
sity — the lowest percentages of obese people were 
in the group of the best educated [25]. A systematic 
literature review conducted by Dinsa et al., analysing 
the relationship between socioeconomic status and 
obesity in low-income countries proved that in these 
countries, obesity is more common in the population 
of better educated people and those with higher in-
comes. For middle-income countries, this relationship 
is not equally evident [23, 26].
On the basis of the presented data it is clear that 
obesity, which is an increasingly common health dis-
order, becomes a significant problem from the public 
health point of view. Forecasts regarding the prevalence 
of overweight and obesity assume that, at the current 
growth rate, its prevalence in the world will rise to 
2.16 billion people for overweight and 1.12 billion 
people for obesity in 2030, corresponding jointly to 
58% of the world’s adult population [27]. In view of the 
above, we should expect an equivalent increase in the 
incidence of the most serious health consequences of 
obesity, including type 2 diabetes and selected cancers.
Obesity and type 2 diabetes
For many years, studies have shown that increased 
prevalence of overweight and obesity in the world is 
accompanied by increased prevalence of metabolic 
syndrome and type 2 diabetes mellitus (T2DM) [8]. The 
latter (T2DM) is a chronic disease that is considered to 
be highly correlated with excess body weight. It also 
represents the second-to-obesity disease of civilisa-
tion, which is a growing epidemiological and social, as 
well as economic problem in recent decades. Similar 
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to obesity, the reasons for the increasing proportion 
of patients with diabetes are believed to be related to 
lifestyle changes, including urbanisation, change in 
eating habits and reduced physical activity, as well as 
ageing of the population [28].
In countries with a high income type 2 diabetes 
represents between 85% to 95% of all diabetes cases 
[29, 30], and over the last few years many reports have 
been prepared and published on the epidemiology of 
diabetes, as well as forecasts of its expected prevalence 
in the future. Currently, the most recent estimates of 
the incidence, prevalence and projected morbidity of 
diabetes in the world were published by the Interna-
tional Diabetes Federation (IDF) in the sixth edition of 
the Diabetes Atlas [30].
The data available to the IDF indicate that in 
2014 diabetes affected 387 million people, or 8.3% of 
the world’s population (type 1 and 2 combined), and 
by 2035 this figure will increase to 592 million [30]. 
In 2014, diabetes was the cause of 4.9 million deaths 
worldwide [30]. According to IDF, in 1980 the number 
of patients with diabetes globally was 153 million, 
which means an increase of 234 million cases over 
34 years [31]. More than half of the adult popula-
tion diagnosed with diabetes are individuals between 
40 and 59 years of age, 80% of them living in countries 
with low and middle income. The forecasts assume that 
by 2035, 86% of people in this age group will live in 
countries with low and middle income [30].
In Europe, in 2014 diabetes was diagnosed in 
52 million people aged 20 to 79 years, representing 
7.9% of the adult population. The number of people with 
undiagnosed diabetes in Europe in 2014 was 17.2 mil-
lion, giving a total diabetic population of 69.2 million. In 
2035, the projected prevalence of diabetes in Europe is 
68.9 million, which means a 22% increase as compared 
with the figure of 2013 for this region [30].
Similar estimates for Poland indicate that in 
2014 diabetes was diagnosed in approximately 
2.05 million people. It is estimated that undiagnosed 
diabetes was present in this period in approximately 
0.70 million of Poles, giving a total diabetic popula-
tion of 2.75 million [30]. It is worth emphasising that, 
according to the IDF, Poland is among 10 countries 
with the highest percentage of people with impaired 
glucose tolerance (4th place, 16.5%), and according to 
forecasts, in 2035 Poland will reach the top of the rank-
ing in terms of this parameter (19.3%) [30]. According 
to the database records of the National Health Fund, 
in Poland in 2013 there were 2,312,919 patients regis-
tered, who utilized diabetes-related medical services or 
purchased anti-diabetic medications and/or test strips, 
while in 2014 this number was 2,431,611 patients.
The forecasts regarding prevalence of diabetes 
among US residents indicate that, assuming low in-
crease in incidence and high mortality associated with 
diabetes, in 2050 diabetes (diagnosed or undiagnosed) 
will affect 21% of the adult US population [32]. As-
suming no change in the incidence rate for diabetes, 
its prevalence in the adult population of the United 
States can reach as much as 33% [32].
United Kingdom is a country with one of the high-
est percentages of obese people in the world [12]. The 
performed analyses indicate an alarmingly high preva-
lence of both obesity and type 2 diabetes in the popula-
tions of England, Scotland, Wales and Northern Ireland 
[33, 34]. In 2013, in England, people with obesity or 
overweight accounted for 62% of the adult population, 
whereas 6% of the adult population were diagnosed 
with diabetes. Given the high percentage of undiag-
nosed diabetes, it should be assumed that approxi-
mately 7.4% of the adult population in England has 
diabetes [33, 34]. The National Diabetes Audit also indi-
cated that in the years 2009–2010, approximately 90% 
of English people aged 16–54 diagnosed with type 2 
diabetes were obese or overweight, and 12.4% of 
obese English population above 18 years of age were 
diagnosed with diabetes. This gives a 5-fold higher inci-
dence of type 2 diabetes in obese people than in those 
with normal body weight (the prevalence of diabetes 
in adults with normal body weight was estimated at 
2.4%) [33–35].
The causal link between excess body weight and 
type 2 diabetes mellitus has been confirmed in many 
studies. The analyses performed focused not only on 
the relationship between the presence of overweight 
and obesity and the risk of type 2 diabetes, but also the 
risk of type 2 diabetes depending on the time of occur-
rence of excess body weight, the degree of overweight 
and obesity, and their duration.
In 1990, the Nurses’ Health Study analysed the 
risk of type 2 diabetes in women depending on BMI, 
over the years 1976 to 1984. The results suggest that 
even with BMI between 23 and 23,9 kg/m2 the risk 
of developing type 2 diabetes is 3.6 times higher 
compared to BMI < 22 kg/m2. This risk increases with 
increasing BMI values. The results obtained in the 
cohort of women have been confirmed over a longer 
observation period (years 1976–1990) [36, 37]. The 
study by Vinciguerra et al. 2013 demonstrated that 
grade II obesity (BMI > 40 kg/m2) was associated with 
a higher risk of developing diabetes than grade I obesity 
(BMI 30–39.9 kg/m2) [38]. Another study, which exam-
ined the relationship between body weight measured 
with BMI and the risk of developing type 2 diabetes, 
was that by Chan et al., 1994. The results of a 5-year 
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follow-up in a group of 51,529 healthy men showed 
a strong correlation between excess body weight and 
type 2 diabetes — the risk increased with increasing 
BMI values, and the relationship was statistically sig-
nificant for each of the BMI categories > 24 kg/m2. In 
men with BMI > 35 kg/m2, compared to men with 
BMI < 23 kg/m2, with adjustment for such confound-
ing factors as age, smoking and family history, the 
relative risk (RR) for developing type 2 diabetes was 
RR = 42.1 (95% CI: 22.0; 80.6). This study indicated that 
also BMI at the age of 21 years, total weight gain after 
the age of 21 years and abdominal obesity measured by 
the waist to hip ratio (WHR) coefficient are independent 
risk factors for developing type 2 diabetes [39].
A meta-analysis of the results of 15 cohort studies 
showed a stronger relationship between type 2 dia-
betes and early weight gain than between type 2 dia-
betes and late weight gain, although the difference 
between groups was not statistically significant. The 
early weight gain was defined as occurring in relation 
to body weight in the age of 18–24 years, whereas 
late weight gain was defined as the gain relative to 
baseline body weight measured at the age of 25 years 
or later. All studies included in the analyses indicated 
a statistically significant association between excess 
body weight and the development of diabetes. The 
relative risk for developing diabetes in case of early 
incremental weight gain by 5 kg m-2 in the early adult-
hood was RR = 3.07 (95% CI: 2.49; 3.97; p < 0.0001), 
and for late weight gain it was RR = 2.12 (95% CI: 
1.74; 2.58; p < 0.0001) [40].
Of importance from the public health point of view 
is also the question of factors resulting from abnormal 
body weight, which increase the risk of developing type 2 
diabetes in obese people. It was found that these risk 
factors include the location of body fat and the dura-
tion of disease. 
In terms of fat distribution, there are two types 
of obesity — central obesity and peripheral obesity. 
Research suggests that, in addition to BMI, waist cir-
cumference is also an indicator showing correlation 
between excess body weight and type 2 diabetes [41]. 
According to reports, waist circumference in excess 
of 102 cm for men and 88 cm for women is strongly 
correlated with the risk of medical complications such 
as type 2 diabetes, cardiovascular complications and 
arterial hypertension [42].
While the relationship between excess body weight 
and the risk of type 2 diabetes has been widely recog-
nised and confirmed, results of the studies examining 
the correlation between the duration of obesity and 
type 2 diabetes are not fully consistent. Most reports, 
however, indicate that such a relationship does exist 
[43–45]. A cohort study conducted on a population 
of 1,256 people to verify the above relationship with 
a follow-up of 48 years demonstrated a relationship 
between the duration of obesity and the risk of diabe-
tes. The hazard ratio (HR), unadjusted for confounders, 
for developing diabetes in men is HR = 1.13 (95% CI: 
1.09; 1.17) and in women HR = 1.12 (95% CI: 1.08; 
1.16) for additional 2 years of obesity. Adjustment for 
confounding factors does not introduce significant 
changes in the obtained results [46].
While analysing the risk of type 2 diabetes in people 
with BMI > 25 kg/m2, we should also have in mind 
that not all obese people have the other elements of 
metabolic syndrome. According to literature, approxi-
mately 30% of obese people do not present these other 
features, and they are referred to as “metabolically 
healthy” [47, 48]. A meta-analysis comparing the risk 
of type 2 diabetes in “metabolically healthy” obese 
patients and “metabolically healthy” persons with 
normal body weight showed a 4-fold higher risk of 
type 2 diabetes in the obese group (RR = 4.03; 95% CI: 
2.66; 6.09). Similarly, in a group of obese patients with 
comorbid additional factors of metabolic syndrome, 
compared to those of normal body weight, the relative 
risk of type 2 diabetes was RR = 8.93 (95% CI: 6.86; 
11.62) [49].
Obesity is also an important factor increasing the 
overall risk of death and death from any cause, as 
well as death from coexisting type 2 diabetes. Avail-
able scientific reports indicate the significant role of 
obesity in increasing the risk of death due to type 
2 diabetes relative to a normal body weight (HR = 0.79; 
95% CI: 0.77; 0.82 in the group with BMI = 15– 
–25 kg/m2 vs. HR = 1.29; 95% CI: 1.27; 1.32 in the 
group with BMI > 25 kg/m2) [50].
Obesity and cancer
While type 2 diabetes is a very well documented 
health consequence of abnormal body weight, the re-
lationship between obesity and carcinogenesis became 
the subject of epidemiological studies only in the late 
twentieth century. As significant interest in these issues 
has emerged over the recent years, there has been 
an increasing amount of scientific evidence for a link 
between obesity and the risk of certain malignancies 
and death due to cancer [11, 51]. This interest is further 
exacerbated by the increasing rate of the epidemic 
incidence of both obesity and cancer. 
Initial reports analysing the relationship between 
abnormal body weight and risk of cancer were pub-
lished already in the 70s of the twentieth century. The 
study by Lew et al., conducted on a population of 
750,000 adults in the years 1959 to 1972, suggested 
www.dk.viamedica.pl
Diabetologia Kliniczna 2015, tom 4, nr 4
168
a relationship between overweight and obesity and 
increased risk of death from cancer [52].
In 2001, the International Agency for Research on 
Cancer (IARC) announced that excessive body weight is 
associated with an increased risk of developing several 
types of cancer. This report indicated that obesity may 
be associated with 11% of cases of colon cancers, 9% 
of breast cancers in postmenopausal women, 39% of 
endometrial cancers, 25% of renal cancers, and 37% of 
cases of oesophageal adenocarcinoma [53]. This was 
the first official statement emphasising the role of ex-
cess body weight as a modifiable risk factor associated 
with the development of cancer. It started the era of 
research on the mechanisms of carcinogenesis in the 
context of the pathophysiology of obesity. In 2007, in 
its publication “Food, Nutrition, Physical Activity and 
the Prevention of Cancer” based on a literature review, 
the World Cancer Research Fund indicated a relation-
ship between high BMI values and the risk of cancer 
of the oesophagus, pancreas, colon, breast cancer in 
postmenopausal women, cancer of the endometrium, 
kidney and the likely relationship with the risk of cancer 
of the gallbladder. An inverse relationship was then 
described between BMI and the risk of breast cancer in 
premenopausal women, and lung cancer (higher BMI 
value seems to be a protective factor) [54].
The results of one of the largest population-based 
studies, whose main objective was to analyse the causal 
relationship between obesity and the risk of develop-
ment of cancer, was published in 2003. It was then 
demonstrated that obesity with a BMI of > 40 kg/m2 in 
a period of 25 years is associated with a relative risk 
of death of 1.52 (95% CI: 1.13; 2.05) in men and 
1.62 (95% CI: 1.40; 1.87) in women [55]. This study 
also highlighted the link between obesity and the 
risk of other neoplasms than those indicated by the 
IARC — pancreatic cancer, liver cancer, non-Hodgkin 
lymphoma and leukaemia. Compared to women with 
BMI values of < 25 kg/m2, women with overweight or 
obesity had a risk of developing cancer higher by 8% 
(for BMI = 25–29.9 kg/m2), by 18% (for BMI = 30– 
–34,9 kg/m2), by 32% (for BMI = 35–39.9 kg/m2) and 
by 62% (for BMI > 40 kg/m2). For men, only BMI values 
of > 30 kg/m2 were correlated with a higher risk of 
developing cancer; the respective percentages were: 
9% for BMI = 30–34.9 kg/m2, 20% for BMI = 35– 
–39.9 kg/m2, and 52% for BMI > 40 kg/m2 [55]. 
The relationship between obesity and deaths from 
selected types of cancer was confirmed later by an 
analysis carried out on the basis of published studies 
on the populations of Europe and North America. This 
analysis included 900,000 adults. The results confirmed 
that for both sexes the risk of death is lowest in the 
groups, in which BMI values corresponded to normal 
body weight (22.5–25 kg/m2). It was also proved that 
any increase in BMI by 5 kg/m2 was accompanied by 
a 5% increase in the risk of death from cancer, and 
a 30% increase in risk of death from any cause [50].
In 2008, Renehan et al. conducted a systematic 
literature review to analyse the relationship between 
obesity and the risk of malignancy. The results of the 
review showed that in men an increase in BMI by 
5 kg/m2 was strongly correlated with increased risk of de-
veloping adenocarcinoma of the oesophagus (RR = 1.52, 
p < 0.0001), thyroid (RR = 1.33; p = 0.02), large in-
testine (RR = 1.24; p < 0.0001) and kidney (RR = 1.24; 
p < 0.0001). In women, there was a strong correlation 
between BMI increase by 5 kg/m2 and increased risk 
of endometrial cancer (RR = 1.59, p ≤ 0.0001), gall-
bladder cancer (RR = 1.59, p = 0.04), oesophageal 
adenocarcinoma (RR = 1.51; p < 0.0001) and kidney 
cancer (RR = 1.34; p < 0.0001). There was poor cor-
relation (RR < 1.20) between increased BMI and the risk 
of rectal cancer and malignant melanoma in men, and 
postmenopausal breast cancer, pancreatic, thyroid and 
colon cancer in women, and leukaemia, non-Hodgkin 
lymphoma and multiple myeloma in both sexes [51].
One of the well documented relationships is the 
effect of obesity on the risk of developing colon cancer. 
This relationship has been the subject of numerous 
cohort studies [56–58]. It has been observed that it 
is stronger for men than for women. Due to the high 
variability of the effect magnitude reported in the 
studies, this relationship was also analysed in the con-
text of systematic reviews and metaanalyses, aimed 
to provide information on the cumulative amount of 
risk. A systematic review by Ma et al. Performed in 
2013 [59] included the results of 41 prospective cohort 
studies that investigated the relationship to BMI, and 
13 studies in which the evaluated parameter was waist 
circumference. Excessive values of both BMI and waist 
circumference, which is the indicator of abdominal 
obesity, were correlated with a higher risk of develop-
ing colorectal cancer compared to the population with 
normal values of these parameters. The relative risk 
of developing colorectal cancer for obesity relative to 
a normal body weight, measured with BMI parameter, 
was RR = 1.33 (95% CI: 1.25; 1.42). For the calcula-
tions using waist circumference, this relative risk was 
RR = 1.45 (95% CI: 1.33; 1.60). Stratification by cancer 
site demonstrated the effect of obesity regardless of 
tumour location, for both colon cancer and rectal can-
cer [59]. In the case of stratification by sex, there was 
a higher risk of cancer in both groups, both in case of 
calculations performed using waist circumference and 
BMI, although the risk was higher in men (RR = 1.47, 
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95% CI: 1.36; 1.58 for men vs. RR = 1.15 (95% CI: 1.08; 
1.23 for women) [59]. Similar results were obtained 
in the review by Ning et al., which also included the 
results of retrospective studies. The review also dem-
onstrated that each increase in BMI by 5 kg/m2 was 
associated with an increase in the risk of developing 
cancer by 18% [60].
A systematic review with metaanalysis of the re-
sults, which sought to examine whether obese people 
are screened more often for colorectal cancer compared 
to those of normal weight (BMI: 18.5–24.9 kg/m2), 
showed no such relationship. Moreover, in the popula-
tion of white obese women, the frequency of screening 
was lower than in the population of white women of 
normal body weight (OR = 0.87, 95% CI: 0.82; 0.93 for 
grade I obesity, BMI: 30–34.9 kg/m2, OR = 0.80, 95% 
CI: 0.65; 0.99 for grade II obesity, BMI: 35–39.9 kg/m2, 
OR = 0.73, 95% CI: 0.58; 0.94 for grade III obesity, 
BMI > 40 kg/m2). In the population of white men, simi-
lar results were obtained only for grade II obesity [61].
The researchers are also interested in breast can-
cer due to its very high incidence and the fact that it 
is the main cause of cancer death in women. Weight 
gain is considered to be associated with the risk of 
breast cancer; however, studies have shown a higher 
incidence of proliferative lesions in overweight post-
menopausal women. A metaanalysis of prospective 
studies showed that postmenopausal women with 
a BMI of 25, 30 and 35 kg/m2 have a relative risk 
of breast cancer of RR = 1.02 (95% CI: 0.98; 1.06), 
RR = 1.12 (95% CI: 1.01; 1.24), and RR = 1.26 (95% CI: 
1.07; 1.50), respectively, compared with women of 
normal body weight [62]. There is, however, no similar 
relationship for premenopausal women. Moreover, the 
published results of studies even suggest a protective 
effect of obesity in these women in the context of the 
risk of developing breast cancer [63]. The results of 
metaanalyses also indicate a worse prognosis in obese 
patients with breast cancer relative to breast cancer 
patients with normal body weight [64]. Higher BMI val-
ues in this population are associated with lower overall 
survival and survival due to breast cancer. The relative 
risk of death from any cause is RR = 1.41 (95% CI: 
1.29; 1.53) for obese people, RR = 1.07 (95% CI: 1.02; 
1.12) for overweight people, and RR = 1.10 (95% CI: 
0.92; 1.31) for underweight people compared to peo-
ple of normal body weight. The relative risk of death 
from breast cancer in obese premenopausal women is 
RR=1.75 (95% CI: 1.26; 2.41), and for postmenopausal 
women RR = 1.34 (95% CI: 1.18; 1.53) compared to 
people of normal body weight [64].
Also the risk of the fourth most common cancer 
in women, i.e. endometrial cancer, appears to be cor-
related with obesity. Epidemiological studies indicate 
different magnitudes of relationships between BMI 
values and the risk of endometrial cancer. However, 
the available quantitative analyses suggest a clear 
link between BMI and the relative risk of develop-
ing this cancer — RR = 1.62, (95% CI: 1.39;1.89) for 
BMI > 25 kg/m2 and RR = 2.54 (95% CI: 2.11; 3.06) 
for obesity, and RR = 1.32 (95% CI: 1.16; 1.50) for 
overweight [65].
For renal cancer, obesity is also considered a risk 
factor increasing the probability of developing the 
disease. Metaanalyses showed a significant associa-
tion between obesity and kidney cancer. Based on 
the available reports, Bergström et al. estimated 
the overall risk of renal cancer in obese people at 
RR = 1.07 (95% CI: 1.05; 1.09) per BMI increase 
of 1 unit (corresponding to body weight gain of 
3 kg for a person with a constant height) [66]. 
Epidemiological studies also point to the greater 
strength of this relationship for women than for men. 
A metaanalysis of cohort studies demonstrated that, 
compared with normal body weight, in overweight 
people the relative risk of developing kidney cancer 
was RR = 1.28 (95% CI: 1.24; 1.33), and for obese 
people this risk was RR = 1.77 (95% CI: 1.68; 1.87). 
The authors of the metaanalysis emphasise that, in 
accordance with the performed quantitative and 
qualitative analysis of the results of epidemiological 
studies, the increased risk seems to apply equally to 
both women and men [67].
The investigators also point out the important role 
of reduction of body weight in the prevention of cancer 
[68]. In 2012 Birks et al. published a systematic review 
aimed to identify scientific reports on the relationship 
between body weight loss and the risk of neoplastic 
changes, as well as the risk of death from cancer. The 
review included 34 studies. The results suggest a rela-
tionship between body weight loss and reduced risk of 
cancer. The results of 16 out of 34 studies included in 
this review confirmed this relationship. This correlation 
was clearly visible only in women and it was present for 
all types of cancers considered obesity-related (colorec-
tal cancer, breast cancer in postmenopausal women, 
cancers of the endometrium, kidney, oesophagus and 
pancreas) [68].
The relationship between abnormal body weight 
and the risk of developing certain cancers is supported 
by high-quality scientific evidence. It has been repeat-
edly confirmed in metaanalyses of the results of avail-
able research. Importantly, however, the correlation 
between obesity and certain malignancies is still not 
entirely clear, or remains unknown, and thus requires 
further studies. 
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Conclusions
Both obesity and type 2 diabetes mellitus and 
cancer are among the most common chronic diseases 
today. The data collected by global organisations for 
the protection and promotion of health indicate a sharp 
increase in the incidence of these diseases in the past 
few decades. This is due, on one hand, to the constantly 
increasing human life expectancy, and on the other 
hand, to changes in lifestyle, consisting in decreasing 
level of physical activity and the consumption of highly 
processed foods in quantities exceeding the caloric 
needs of the body. 
The epidemiological studies presented above and 
concerning the prevalence and the relationship be-
tween abnormal body weight and type 2 diabetes and 
cancer often differ in the selection criteria of the study 
groups, their sizes, age ranges of the included popula-
tions, as well as their timeframes. These factors may 
slightly affect the results of these studies. However, on 
this basis, it is apparent that there are some tendencies 
and trends in the occurrence and the mutual relation-
ships between obesity, type 2 diabetes and cancer. 
Importantly, the results of epidemiological stud-
ies allow concluding that the epidemic of obesity is 
becoming a major problem not only in developed 
countries but also in developing countries with low 
and middle income. They also point to a significant 
correlation between excess body weight and the risk 
of type 2 diabetes. This risk appears to be greatest in 
those with the highest values of BMI and abdominal 
type of obesity (central obesity).
The significantly higher incidence of certain cancers 
in patients with abnormal body weight identifies an 
important modifiable risk factor for carcinogenesis, 
which is obesity. This is extremely important from the 
cancer prevention point of view. This relationship fur-
ther underscores the importance of obesity as a disease 
of civilisation, which is a major threat to public health, 
and points to the need for further research focused on 
identifying pathophysiological links between obesity 
and cancer, and type 2 diabetes.
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